Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells

Neuroscience Bulletin

Volumn 24, Issue 1, 2008, Pages 34-38

  Huang, Chui Xue ^a   Hou, Yong Hong ^b   Liu, Yun Sheng ^b  

^a HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Galectin 3; Invasiveness; Pituitary neoplasma

Indexed keywords

GALECTIN 3; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; BAX PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHILD; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; ADENOMA; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADENOMA; ADOLESCENT; ADULT; AGED; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CHILD; FEMALE; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; YOUNG ADULT;

EID: 46149096222     PISSN: 16737067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12264-008-1029-y     Document Type: Article

References (22)

1. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002, 1572: 263-273.
2. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000, 156: 899-909.
3. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002, 277: 6852-6857.
4. Kawatani M, Imoto M. Deletion of the BH1 domain of Bcl-2 accelerates apoptosis by acting in a dominant negative fashion. J Biol Chem 2003, 278: 19732-19742.
5. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 2002, 9:103-113.
6. Gong JY, Shi JX, Liu CJ, Hang CH, Cheng HL, Yin HX. The role of cell proliferating nuclear antigen on predicting the recurrence of postoperative pituitary adenomas. Chin J Neurosurg 2001, 17: 11-13.
7. Hardy J, Vezina JL. Transsphenoidal neurosurgery of intracranial neoplasm. Adv Neurol 1976, 15: 261-273.
8. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993, 33: 610-618.
9. Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, et al. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and-9. Biochemistry 1994, 33: 14109-14114.
10. Yu F, Finley RL Jr, Raz A, Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome C release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 2002, 277: 15819-15827.
11. Raz A, Zhu DG, Hogan V, Shah N, Raz T, Karkash R, et al. Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer 1990, 46: 871-877.
12. Schoeppner HL, Raz A, Ho SB, Bresalier RS. Expression of an endogenous galactoside-binding lectin correlates with neoplastic progression in the colon. Cancer 1995, 75: 2818-2826.
13. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, et al. Metastasis of human colon cancer is altered by modifying expression of the β-galactoside-binding protein galectin-3. Gastroenterology 1998, 115: 287-296.
14. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, Tahara E. Expression of a 31 kDa lactose-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 1994, 56: 474-480.
15. van den Brûle FA, Engel J, Stetler-Stevenson WG, Liu FT, Sobel ME, Castronovo V. Genes involved in tumor invasion and metastasis are differentiall y modulated by estradiol and progestin in human breast cancer cells. Int J Cancer 1992, 52: 653-657.
16. Nangia-Makker P, Sarvis R, Visscher DW, Bailey-Penrod J, Raz A, Sarkar FH. Galectin-3 and L1 retrotransposons in human breast carcinomas. Breast Cancer Res Treat 1998, 49: 171-183.
17. Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF Jr, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003, 63: 2251-2255.
18. Wang H, Wang MD, Ma WB, Yang D, Shi YF, Kong YG, et al. Expression of galectin-3 in invasive prolactinomas. Acta Academia Medicinae Sinica 2005, 27: 380-381.
19. Jin L, Riss D, Ruebel K, Kajita S, Scheithauer BW, Horvath E, et al. Galectin-3 expression in functioning and silent ACTH-producing adenomas. Endocr Pathol 2005, 16: 107-114.
20. Thodou E, Argyrakos T, Kontogeorgos G. Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones (Athens) 2007, 6: 227-232.
21. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997, 57: 5272-5276.
22. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002, 277: 6852-6857.